IL239898B - Therapeutic compositions and methods involving mrna transfection - Google Patents

Therapeutic compositions and methods involving mrna transfection

Info

Publication number
IL239898B
IL239898B IL239898A IL23989815A IL239898B IL 239898 B IL239898 B IL 239898B IL 239898 A IL239898 A IL 239898A IL 23989815 A IL23989815 A IL 23989815A IL 239898 B IL239898 B IL 239898B
Authority
IL
Israel
Prior art keywords
processes involving
medicinal compositions
mrna transfection
involving mrna
transfection
Prior art date
Application number
IL239898A
Other languages
English (en)
Hebrew (he)
Other versions
IL239898A0 (en
Inventor
C Herzberg Mark
R Sorenson Brent
Farnie Ross Karen
Original Assignee
C Herzberg Mark
C Herzberg Mark
R Sorenson Brent
Farnie Ross Karen
Farnie Ross Karen
R Sorenson Brent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C Herzberg Mark, C Herzberg Mark, R Sorenson Brent, Farnie Ross Karen, Farnie Ross Karen, R Sorenson Brent filed Critical C Herzberg Mark
Publication of IL239898A0 publication Critical patent/IL239898A0/en
Publication of IL239898B publication Critical patent/IL239898B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL239898A 2013-01-11 2015-07-12 Therapeutic compositions and methods involving mrna transfection IL239898B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751504P 2013-01-11 2013-01-11
PCT/US2014/011041 WO2014110366A1 (en) 2013-01-11 2014-01-10 Therapeutic compositions and methods involving mrna transfection

Publications (2)

Publication Number Publication Date
IL239898A0 IL239898A0 (en) 2015-08-31
IL239898B true IL239898B (en) 2018-10-31

Family

ID=51167392

Family Applications (2)

Application Number Title Priority Date Filing Date
IL239898A IL239898B (en) 2013-01-11 2015-07-12 Therapeutic compositions and methods involving mrna transfection
IL262252A IL262252B (en) 2013-01-11 2018-10-10 Therapeutic compositions and methods involving mrna transfection

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL262252A IL262252B (en) 2013-01-11 2018-10-10 Therapeutic compositions and methods involving mrna transfection

Country Status (13)

Country Link
US (3) US20150344537A1 (https=)
EP (2) EP2943226B1 (https=)
JP (4) JP2016511230A (https=)
KR (2) KR102119985B1 (https=)
CN (1) CN105473163A (https=)
AU (1) AU2014205298B2 (https=)
CA (2) CA2901409C (https=)
ES (1) ES2738315T3 (https=)
IL (2) IL239898B (https=)
NZ (1) NZ710495A (https=)
PL (1) PL2943226T3 (https=)
SG (2) SG11201505431XA (https=)
WO (1) WO2014110366A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344537A1 (en) * 2013-01-11 2015-12-03 Mark C. Herzberg Non-Transgene Transfection for Therapeutic Purposes
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
CN107841508A (zh) * 2017-11-29 2018-03-27 重庆市中医院 含抑铁素重组减毒沙门杆菌及构建方法、表达或递送载体
EP3553523A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
EP3553525A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Diagnostics of mild or advanced periodontitis
JP6891157B2 (ja) * 2018-11-15 2021-06-18 正生 池本 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
CN114561381A (zh) * 2022-03-14 2022-05-31 桂林医学院 免疫mRNA及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2797402B1 (fr) * 1999-07-15 2004-03-12 Biomerieux Stelhys Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune
WO2001023002A1 (en) * 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
WO2002022686A2 (en) * 2000-09-15 2002-03-21 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US20070123455A1 (en) * 2003-04-04 2007-05-31 Joel Palefsky Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (de) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8/Mrp14 Inhibitoren und ihre Verwendung zur Prävention und/oder Behandlung von hypertrophen Narben und Keloiden
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2006078717A2 (en) * 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
KR100681763B1 (ko) * 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US8679811B2 (en) * 2007-06-11 2014-03-25 The University Of Vermont And State Agricultural College Treatments involving glutaredoxins and similar agents
US8916163B1 (en) * 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
DE102010040153A1 (de) * 2010-09-02 2012-03-08 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Stoffkombination zur Behandlung von entzündlichen oder infektiösen Erkrankungen
EP2691101A2 (en) * 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US10174081B2 (en) * 2011-04-21 2019-01-08 George Mason Research Foundation, Inc. Antimicrobial peptides and uses therefore
US20150344537A1 (en) * 2013-01-11 2015-12-03 Mark C. Herzberg Non-Transgene Transfection for Therapeutic Purposes

Also Published As

Publication number Publication date
JP2016511230A (ja) 2016-04-14
AU2014205298A1 (en) 2015-08-13
SG10201603946PA (en) 2016-07-28
US20200231640A1 (en) 2020-07-23
KR102056511B1 (ko) 2019-12-16
EP2943226B1 (en) 2019-03-13
IL239898A0 (en) 2015-08-31
US11912744B2 (en) 2024-02-27
JP2019031521A (ja) 2019-02-28
JP2021019644A (ja) 2021-02-18
KR20160031999A (ko) 2016-03-23
CA2901409C (en) 2022-06-07
WO2014110366A1 (en) 2014-07-17
IL262252B (en) 2020-06-30
ES2738315T3 (es) 2020-01-21
AU2014205298B2 (en) 2018-11-01
EP2943226A1 (en) 2015-11-18
JP6956059B2 (ja) 2021-10-27
US20150344537A1 (en) 2015-12-03
CN105473163A (zh) 2016-04-06
EP3501551A1 (en) 2019-06-26
KR20180026811A (ko) 2018-03-13
SG11201505431XA (en) 2015-08-28
NZ710495A (en) 2019-10-25
KR102119985B1 (ko) 2020-06-05
US20240166701A1 (en) 2024-05-23
PL2943226T3 (pl) 2019-09-30
EP3501551C0 (en) 2023-06-07
IL262252A (en) 2018-11-29
CA3152721A1 (en) 2014-07-17
CA2901409A1 (en) 2014-07-17
US12448421B2 (en) 2025-10-21
JP6473729B2 (ja) 2019-02-20
EP2943226A4 (en) 2016-11-23
EP3501551B1 (en) 2023-06-07
JP2017052781A (ja) 2017-03-16
CA3152721C (en) 2025-11-18

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
IL269045B (en) Aptamers and uses thereof
IL286759A (en) Therapeutic methods and preparations
EP2953474A4 (en) COMPOSITIONS AND METHODS
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
PL2969227T3 (pl) Formulacja octanu abirateronu
HRP20181994T1 (hr) Neuroaktivni steroidi i postupci za njihovu upotrebu
LT2968221T (lt) S-ketamino hidrochlorido farmacinė kompozicija
DK3049117T3 (da) Ultralydsmedieret afgivelse af lægemidler
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
PL2830654T3 (pl) Sposoby i kompozycje do leczenia zapalenia
DK3038674T3 (da) Medikamentafgivelsesindretning
SG11201508167PA (en) Therapeutic compositions and uses thereof
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
IL282430A (en) Anti-cancer agents and preparation thereof
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
DK3068505T3 (da) Spillesystem og -fremgangsmåde
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
PL3145508T3 (pl) Nanocząstki klewidypiny i ich kompozycje farmaceutyczne
PL3228313T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
EP2996685A4 (en) FLUID PROCESSING COMPOSITIONS AND METHODS
FR3007291B1 (fr) Composition cicatrisante et utlisation
DK2983747T3 (da) Lægemiddelindgivelsesindretning
BR112014017217A8 (pt) agente e composição farmacêutica

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed